Financial Performance - Total revenue for 2024 was CNY 349.63 million, a decrease of 13.28% compared to the previous year[4] - Operating profit reached CNY 7.55 million, a significant increase of 102.07% year-on-year[4] - Net profit attributable to the parent company was CNY -2.07 million, a reduction in losses of 99.45% compared to the previous year[7] - Basic earnings per share improved to CNY -0.04, a significant reduction in losses compared to CNY -6.38 in the previous year[5] Assets and Equity - The total assets at the end of the reporting period were CNY 3,738.07 million, down 4.31% from the beginning of the period[8] - The equity attributable to the parent company decreased by 4.60% to CNY 3,248.58 million[8] Cost Management and Efficiency - The company focused on cost reduction and efficiency improvement, leading to a significant decrease in operating expenses[8] - Research and development expenses, although decreased, maintained a relatively high intensity, with a focus on resource allocation based on market demand[8] - The company reported a substantial decrease in impairment losses compared to the previous year, enhancing asset management efficiency[8] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the annual report[10]
硕世生物(688399) - 2024 Q4 - 年度业绩